[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fp4OJRwQodK84nwsQStJkA1DeikCewugpSDxGFrWncAg":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":42,"rows":49},"Kessler Foundation",[4],171,false,49,0,8890,1,151,[14,17,20,23,26,29,32,34],{"name":15,"count":16},"Traumatic Brain Injury",35,{"name":18,"count":19},"Multiple Sclerosis",26,{"name":21,"count":22},"Stroke",22,{"name":24,"count":25},"Spinal Cord Injuries",17,{"name":27,"count":28},"Spinal Cord Injury",12,{"name":30,"count":31},"Spatial Neglect",6,{"name":33,"count":31},"SCI - Spinal Cord Injury",{"name":35,"count":31},"Cognitive Impairment",[37],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT07159100","tDCS for Cancer-Related Fatigue and Weakness","2027-08-31","Sham tDCS + elbow flexion exercise",[43,44,45,46,47,48],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[50,74,101,129,147,174,201,219,243,270,298,323,349,367,393,411,436,459,487,520,545,567,590,615],{"intervention":41,"totalTrials":11,"cells":51},{"EARLY_PHASE1":52,"PHASE1":64,"PHASE2":66,"PHASE3":68,"PHASE4":70,"NA":72},{"trials":53,"activeCount":11,"soonestReadout":40},[54],{"nctId":38,"briefTitle":39,"status":55,"phases":56,"primaryCompletion":40,"completion":57,"start":58,"enrollment":59,"conditions":60,"interventions":63},"NOT_YET_RECRUITING",[43],"2027-12-31","2025-09-10",75,[61,62],"Cancer-related Fatigue","Neuromodulation",[41],{"trials":65,"activeCount":9},[],{"trials":67,"activeCount":9},[],{"trials":69,"activeCount":9},[],{"trials":71,"activeCount":9},[],{"trials":73,"activeCount":9},[],{"intervention":75,"totalTrials":11,"cells":76},"Ramelteon",{"EARLY_PHASE1":77,"PHASE1":79,"PHASE2":81,"PHASE3":83,"PHASE4":85,"NA":99},{"trials":78,"activeCount":9},[],{"trials":80,"activeCount":9},[],{"trials":82,"activeCount":9},[],{"trials":84,"activeCount":9},[],{"trials":86,"activeCount":9},[87],{"nctId":88,"briefTitle":89,"status":90,"phases":91,"primaryCompletion":92,"completion":92,"start":93,"enrollment":94,"conditions":95,"interventions":98},"NCT01207050","Effect of Rozerem on Sleep Among People With Traumatic Brain Injury","UNKNOWN",[47],"2014-12","2010-09",20,[96,97],"Insomnia","Brain Injury",[75],{"trials":100,"activeCount":9},[],{"intervention":102,"totalTrials":11,"cells":103},"6% aqueous phenol",{"EARLY_PHASE1":104,"PHASE1":106,"PHASE2":108,"PHASE3":110,"PHASE4":112,"NA":127},{"trials":105,"activeCount":9},[],{"trials":107,"activeCount":9},[],{"trials":109,"activeCount":9},[],{"trials":111,"activeCount":9},[],{"trials":113,"activeCount":9},[114],{"nctId":115,"briefTitle":116,"status":90,"phases":117,"primaryCompletion":118,"completion":119,"start":120,"enrollment":121,"conditions":122,"interventions":125},"NCT04989660","Phenol Neurolysis of Genicular Nerves for Osteoarthritic Knee Pain",[47],"2023-08","2023-10","2021-11-01",30,[123,124],"Osteoarthritis, Knee","Knee Pain Chronic",[102,126],"Isotonic saline",{"trials":128,"activeCount":9},[],{"intervention":126,"totalTrials":11,"cells":130},{"EARLY_PHASE1":131,"PHASE1":133,"PHASE2":135,"PHASE3":137,"PHASE4":139,"NA":145},{"trials":132,"activeCount":9},[],{"trials":134,"activeCount":9},[],{"trials":136,"activeCount":9},[],{"trials":138,"activeCount":9},[],{"trials":140,"activeCount":9},[141],{"nctId":115,"briefTitle":116,"status":90,"phases":142,"primaryCompletion":118,"completion":119,"start":120,"enrollment":121,"conditions":143,"interventions":144},[47],[123,124],[102,126],{"trials":146,"activeCount":9},[],{"intervention":148,"totalTrials":11,"cells":149},"Methelphenidate",{"EARLY_PHASE1":150,"PHASE1":152,"PHASE2":154,"PHASE3":168,"PHASE4":170,"NA":172},{"trials":151,"activeCount":9},[],{"trials":153,"activeCount":9},[],{"trials":155,"activeCount":9},[156],{"nctId":157,"briefTitle":158,"status":159,"phases":160,"primaryCompletion":161,"completion":162,"start":163,"enrollment":164,"conditions":165,"interventions":167},"NCT02286557","Testing the Effects of Methylphenidate on Multiple Sclerosis","COMPLETED",[45],"2025-02-28","2025-03-04","2014-10",36,[166],"Fatigue in Multiple Sclerosis",[148],{"trials":169,"activeCount":9},[],{"trials":171,"activeCount":9},[],{"trials":173,"activeCount":9},[],{"intervention":175,"totalTrials":11,"cells":176},"Oxybutynin Chloride IR",{"EARLY_PHASE1":177,"PHASE1":179,"PHASE2":181,"PHASE3":195,"PHASE4":197,"NA":199},{"trials":178,"activeCount":9},[],{"trials":180,"activeCount":9},[],{"trials":182,"activeCount":9},[183],{"nctId":184,"briefTitle":185,"status":90,"phases":186,"primaryCompletion":187,"completion":188,"start":189,"enrollment":190,"conditions":191,"interventions":193},"NCT03187795","Mirabegron and Oxybutynin Safety and Efficacy Trial in Spinal Cord Injury",[45],"2021-09-30","2022-03-30","2019-04-03",62,[24,192],"Urinary Bladder, Neurogenic",[175,194],"Mirabegron",{"trials":196,"activeCount":9},[],{"trials":198,"activeCount":9},[],{"trials":200,"activeCount":9},[],{"intervention":194,"totalTrials":11,"cells":202},{"EARLY_PHASE1":203,"PHASE1":205,"PHASE2":207,"PHASE3":213,"PHASE4":215,"NA":217},{"trials":204,"activeCount":9},[],{"trials":206,"activeCount":9},[],{"trials":208,"activeCount":9},[209],{"nctId":184,"briefTitle":185,"status":90,"phases":210,"primaryCompletion":187,"completion":188,"start":189,"enrollment":190,"conditions":211,"interventions":212},[45],[24,192],[175,194],{"trials":214,"activeCount":9},[],{"trials":216,"activeCount":9},[],{"trials":218,"activeCount":9},[],{"intervention":220,"totalTrials":11,"cells":221},"Testosterone Gel applied by a pump",{"EARLY_PHASE1":222,"PHASE1":224,"PHASE2":226,"PHASE3":237,"PHASE4":239,"NA":241},{"trials":223,"activeCount":9},[],{"trials":225,"activeCount":9},[],{"trials":227,"activeCount":9},[228],{"nctId":229,"briefTitle":230,"status":90,"phases":231,"primaryCompletion":232,"completion":232,"start":233,"enrollment":234,"conditions":235,"interventions":236},"NCT02317640","TRT in Combination With Electrical Stimulation and Standing: Effect on Muscle and Bone in Spinal Cord Injured Males",[44,45],"2022-10","2017-03-15",56,[27],[220],{"trials":238,"activeCount":9},[],{"trials":240,"activeCount":9},[],{"trials":242,"activeCount":9},[],{"intervention":244,"totalTrials":11,"cells":245},"Normal Saline",{"EARLY_PHASE1":246,"PHASE1":248,"PHASE2":250,"PHASE3":264,"PHASE4":266,"NA":268},{"trials":247,"activeCount":9},[],{"trials":249,"activeCount":9},[],{"trials":251,"activeCount":9},[252],{"nctId":253,"briefTitle":254,"status":159,"phases":255,"primaryCompletion":256,"completion":256,"start":257,"enrollment":258,"conditions":259,"interventions":263},"NCT04274543","Ultrasound-Guided Injections for Meniscal Injuries in Active-Duty Military",[45],"2024-12-01","2019-07-01",3,[260,261,262],"Tibial Meniscus Injuries","Knee Injuries","Knee Injuries and Disorders",[244],{"trials":265,"activeCount":9},[],{"trials":267,"activeCount":9},[],{"trials":269,"activeCount":9},[],{"intervention":271,"totalTrials":11,"cells":272},"Dexamethasone",{"EARLY_PHASE1":273,"PHASE1":275,"PHASE2":277,"PHASE3":292,"PHASE4":294,"NA":296},{"trials":274,"activeCount":9},[],{"trials":276,"activeCount":9},[],{"trials":278,"activeCount":9},[279],{"nctId":280,"briefTitle":281,"status":90,"phases":282,"primaryCompletion":283,"completion":284,"start":285,"enrollment":286,"conditions":287,"interventions":291},"NCT04136743","Ultrasound-Guided Treatments for Shoulder Pain in Wheelchair Users With Spinal Cord Injury",[45],"2023-04-30","2024-04-30","2019-06-14",24,[24,288,289,290],"Tendinopathy","Rotator Cuff Tears","Shoulder Pain",[271],{"trials":293,"activeCount":9},[],{"trials":295,"activeCount":9},[],{"trials":297,"activeCount":9},[],{"intervention":299,"totalTrials":11,"cells":300},"Dalfampridine",{"EARLY_PHASE1":301,"PHASE1":303,"PHASE2":305,"PHASE3":317,"PHASE4":319,"NA":321},{"trials":302,"activeCount":9},[],{"trials":304,"activeCount":9},[],{"trials":306,"activeCount":9},[307],{"nctId":308,"briefTitle":309,"status":159,"phases":310,"primaryCompletion":311,"completion":312,"start":313,"enrollment":314,"conditions":315,"interventions":316},"NCT01621113","Combination Therapy With Dalfampridine and Locomotor Training for Chronic, Motor Incomplete Spinal Cord Injury",[45],"2017-10-09","2017-10-16","2012-06",27,[27],[299],{"trials":318,"activeCount":9},[],{"trials":320,"activeCount":9},[],{"trials":322,"activeCount":9},[],{"intervention":324,"totalTrials":11,"cells":325},"Wait first, then levetiracetam",{"EARLY_PHASE1":326,"PHASE1":328,"PHASE2":341,"PHASE3":343,"PHASE4":345,"NA":347},{"trials":327,"activeCount":9},[],{"trials":329,"activeCount":9},[330],{"nctId":331,"briefTitle":332,"status":90,"phases":333,"primaryCompletion":334,"completion":334,"start":335,"enrollment":336,"conditions":337,"interventions":339},"NCT00227461","Levetiracetam (Keppra) to Improve Chronic Aphasia in Post-stroke Patients.",[44],"2021-12","2005-09",50,[338,21],"Aphasia",[324,340],"Levetiracetam first, then wait",{"trials":342,"activeCount":9},[],{"trials":344,"activeCount":9},[],{"trials":346,"activeCount":9},[],{"trials":348,"activeCount":9},[],{"intervention":340,"totalTrials":11,"cells":350},{"EARLY_PHASE1":351,"PHASE1":353,"PHASE2":359,"PHASE3":361,"PHASE4":363,"NA":365},{"trials":352,"activeCount":9},[],{"trials":354,"activeCount":9},[355],{"nctId":331,"briefTitle":332,"status":90,"phases":356,"primaryCompletion":334,"completion":334,"start":335,"enrollment":336,"conditions":357,"interventions":358},[44],[338,21],[324,340],{"trials":360,"activeCount":9},[],{"trials":362,"activeCount":9},[],{"trials":364,"activeCount":9},[],{"trials":366,"activeCount":9},[],{"intervention":368,"totalTrials":11,"cells":369},"Donepezil and self-generated memory training",{"EARLY_PHASE1":370,"PHASE1":372,"PHASE2":385,"PHASE3":387,"PHASE4":389,"NA":391},{"trials":371,"activeCount":9},[],{"trials":373,"activeCount":9},[374],{"nctId":375,"briefTitle":376,"status":90,"phases":377,"primaryCompletion":334,"completion":334,"start":378,"enrollment":379,"conditions":380,"interventions":383},"NCT00457769","Aricept to Improve Functional Tasks in Vascular Dementia",[44],"2007-05",18,[21,381,382],"Vascular Dementia","Memory Deficits",[368,384],"Donepezil and experimenter-administered memory training",{"trials":386,"activeCount":9},[],{"trials":388,"activeCount":9},[],{"trials":390,"activeCount":9},[],{"trials":392,"activeCount":9},[],{"intervention":384,"totalTrials":11,"cells":394},{"EARLY_PHASE1":395,"PHASE1":397,"PHASE2":403,"PHASE3":405,"PHASE4":407,"NA":409},{"trials":396,"activeCount":9},[],{"trials":398,"activeCount":9},[399],{"nctId":375,"briefTitle":376,"status":90,"phases":400,"primaryCompletion":334,"completion":334,"start":378,"enrollment":379,"conditions":401,"interventions":402},[44],[21,381,382],[368,384],{"trials":404,"activeCount":9},[],{"trials":406,"activeCount":9},[],{"trials":408,"activeCount":9},[],{"trials":410,"activeCount":9},[],{"intervention":412,"totalTrials":11,"cells":413},"Platelet-rich plasma (PRP) therapy",{"EARLY_PHASE1":414,"PHASE1":416,"PHASE2":428,"PHASE3":430,"PHASE4":432,"NA":434},{"trials":415,"activeCount":9},[],{"trials":417,"activeCount":9},[418],{"nctId":419,"briefTitle":420,"status":159,"phases":421,"primaryCompletion":422,"completion":422,"start":423,"enrollment":31,"conditions":424,"interventions":427},"NCT01355549","Platelet-Rich Plasma Therapy for Shoulder Pain in Persons With Spinal Cord Injury",[44],"2012-11","2011-05",[290,425,426,27],"Rotator Cuff Tendinitis","Rotator Cuff Syndrome",[412],{"trials":429,"activeCount":9},[],{"trials":431,"activeCount":9},[],{"trials":433,"activeCount":9},[],{"trials":435,"activeCount":9},[],{"intervention":437,"totalTrials":11,"cells":438},"MyoMo orthosis and VR games",{"EARLY_PHASE1":439,"PHASE1":449,"PHASE2":451,"PHASE3":453,"PHASE4":455,"NA":457},{"trials":440,"activeCount":9},[441],{"nctId":442,"briefTitle":443,"status":90,"phases":444,"primaryCompletion":445,"completion":445,"start":446,"enrollment":94,"conditions":447,"interventions":448},"NCT05386537","Combining Wearable Robotic Orthosis With Visual and Haptic Feedback to Enhance the Recovery of Upper Extremity Motor Function and ADL in Persons With Acute SCI",[43],"2024-10-01","2021-04-01",[33],[437],{"trials":450,"activeCount":9},[],{"trials":452,"activeCount":9},[],{"trials":454,"activeCount":9},[],{"trials":456,"activeCount":9},[],{"trials":458,"activeCount":9},[],{"intervention":460,"totalTrials":11,"cells":461},"Autologous micro-fragmented adipose tissue",{"EARLY_PHASE1":462,"PHASE1":477,"PHASE2":479,"PHASE3":481,"PHASE4":483,"NA":485},{"trials":463,"activeCount":9},[464],{"nctId":465,"briefTitle":466,"status":90,"phases":467,"primaryCompletion":468,"completion":469,"start":470,"enrollment":471,"conditions":472,"interventions":476},"NCT03167138","Micro-Fragmented Adipose Tissue (Lipogems®) Injection for Chronic Shoulder Pain in Persons With Spinal Cord Injury",[43],"2019-09-06","2020-02-21","2017-07-14",10,[290,473,474,425,475,24],"Shoulder Impingement Syndrome","Rotator Cuff Impingement Syndrome","Rotator Cuff Syndrome of Shoulder and Allied Disorders",[460],{"trials":478,"activeCount":9},[],{"trials":480,"activeCount":9},[],{"trials":482,"activeCount":9},[],{"trials":484,"activeCount":9},[],{"trials":486,"activeCount":9},[],{"intervention":488,"totalTrials":489,"cells":490},"Modafinil",2,{"EARLY_PHASE1":491,"PHASE1":493,"PHASE2":495,"PHASE3":497,"PHASE4":499,"NA":501},{"trials":492,"activeCount":9},[],{"trials":494,"activeCount":9},[],{"trials":496,"activeCount":9},[],{"trials":498,"activeCount":9},[],{"trials":500,"activeCount":9},[],{"trials":502,"activeCount":9},[503,511],{"nctId":504,"briefTitle":505,"status":159,"phases":506,"primaryCompletion":507,"completion":507,"start":508,"enrollment":94,"conditions":509,"interventions":510},"NCT00142402","Modafinil in Multiple Sclerosis",[48],"2006-09","2003-06",[18],[488],{"nctId":512,"briefTitle":513,"status":90,"phases":514,"completion":515,"start":516,"enrollment":94,"conditions":517,"interventions":519},"NCT00489892","Efficacy of Pharmacological Treatment of Working Memory Impairment After Traumatic Brain Injury: Evaluation With fMRI",[48],"2008-12","2003-08",[15,518],"Severe Traumatic Brain Injury",[488],{"intervention":521,"totalTrials":11,"cells":522},"Zeposia",{"EARLY_PHASE1":523,"PHASE1":525,"PHASE2":527,"PHASE3":529,"PHASE4":531,"NA":533},{"trials":524,"activeCount":9},[],{"trials":526,"activeCount":9},[],{"trials":528,"activeCount":9},[],{"trials":530,"activeCount":9},[],{"trials":532,"activeCount":9},[],{"trials":534,"activeCount":9},[535],{"nctId":536,"briefTitle":537,"status":90,"phases":538,"primaryCompletion":539,"completion":539,"start":540,"enrollment":541,"conditions":542,"interventions":544},"NCT04885894","An Examination of Cognitive Fatigue Using Functional Neuroimaging",[],"2024-12","2022-01-01",60,[543],"Multiple Sclerosis, Relapsing-Remitting",[521],{"intervention":546,"totalTrials":11,"cells":547},"Ocrevus",{"EARLY_PHASE1":548,"PHASE1":550,"PHASE2":552,"PHASE3":554,"PHASE4":556,"NA":558},{"trials":549,"activeCount":9},[],{"trials":551,"activeCount":9},[],{"trials":553,"activeCount":9},[],{"trials":555,"activeCount":9},[],{"trials":557,"activeCount":9},[],{"trials":559,"activeCount":9},[560],{"nctId":561,"briefTitle":562,"status":90,"phases":563,"primaryCompletion":539,"completion":539,"start":564,"enrollment":541,"conditions":565,"interventions":566},"NCT04448977","Examining Effects of Ocrevus on Cognitive Fatigue Using fMRI",[],"2021-05-06",[543],[546],{"intervention":568,"totalTrials":11,"cells":569},"Tysabri",{"EARLY_PHASE1":570,"PHASE1":572,"PHASE2":574,"PHASE3":576,"PHASE4":578,"NA":580},{"trials":571,"activeCount":9},[],{"trials":573,"activeCount":9},[],{"trials":575,"activeCount":9},[],{"trials":577,"activeCount":9},[],{"trials":579,"activeCount":9},[],{"trials":581,"activeCount":9},[582],{"nctId":583,"briefTitle":584,"status":90,"phases":585,"primaryCompletion":539,"completion":539,"start":586,"enrollment":587,"conditions":588,"interventions":589},"NCT04565431","Examining Effects of Tysabri on Cognitive Fatigue Using fMRI",[],"2021-03-19",25,[543],[568],{"intervention":591,"totalTrials":11,"cells":592},"Exposure: Adjuvant chemotherapy treatment",{"EARLY_PHASE1":593,"PHASE1":595,"PHASE2":597,"PHASE3":599,"PHASE4":601,"NA":603},{"trials":594,"activeCount":9},[],{"trials":596,"activeCount":9},[],{"trials":598,"activeCount":9},[],{"trials":600,"activeCount":9},[],{"trials":602,"activeCount":9},[],{"trials":604,"activeCount":9},[605],{"nctId":606,"briefTitle":607,"status":90,"phases":608,"primaryCompletion":609,"completion":609,"start":610,"enrollment":541,"conditions":611,"interventions":613},"NCT02896504","Chemotherapy Effect on Brain Structure, Neurophysiology and Psychomotor Behavior in Breast Cancer Patients",[],"2018-09","2013-09",[612],"Breast Cancer",[591,614],"Exposure: Adjuvant hormonal therapy treatment",{"intervention":614,"totalTrials":11,"cells":616},{"EARLY_PHASE1":617,"PHASE1":619,"PHASE2":621,"PHASE3":623,"PHASE4":625,"NA":627},{"trials":618,"activeCount":9},[],{"trials":620,"activeCount":9},[],{"trials":622,"activeCount":9},[],{"trials":624,"activeCount":9},[],{"trials":626,"activeCount":9},[],{"trials":628,"activeCount":9},[629],{"nctId":606,"briefTitle":607,"status":90,"phases":630,"primaryCompletion":609,"completion":609,"start":610,"enrollment":541,"conditions":631,"interventions":632},[],[612],[591,614]]